Alphabet-founded research and development company Calico Life Sciences LLC announced on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track Designation for ABBV-CLS-628, an investigational therapy for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).
An anti-PAPP-A human monoclonal antibody, ABBV-CLS-628 was developed by Calico in collaboration with AbbVie Inc (NYSE:ABBV). The therapy is currently in a Phase 2 clinical trial evaluating its safety and efficacy in patients with ADPKD.
ABBV-CLS-628 has completed a Phase 1 study in healthy volunteers in which it was shown to be safe and well tolerated with no significant adverse events reported to be associated with the drug.
The ongoing Phase 2 study is now enrolling across approximately 95 sites globally. Participants receive intravenous ABBV-CLS-628 or placebo every 4 weeks for 92 weeks, with safety follow-up for up to 15 weeks. This study is designed to evaluate the safety, tolerability, and potential efficacy of ABBV-CLS-628 in slowing disease progression in ADPKD.
Ananda Pharma achieves key Phase 1 milestone for MRX1 CBD program
Alto Neuroscience receives FDA Fast Track designation for ALTO-101
Calico Life Sciences' investigational treatment for ADPKD receives US FDA Fast Track Designation
Kye Pharmaceuticals' AGAMREE (vamorolone) approved in Canada to treat DMD
XenoSTART and Minerva Imaging expand partnership
Pharming receives FDA priority review for leniolisib in children with APDS
Abbvie invests in US expansion
Ocular Therapeutix prices USD475m common stock offering
Orion's ODM-105 (tasipimidine) insomnia study fails to achieve primary goal
Merck's WINREVAIR reduces clinical worsening by 76% in early PAH patients
Vicore Pharma's buloxibutid receives orphan drug designation in Japan